RetaCalc
Protocol library
SinglePreclinicalPreclinicalVery Low confidenceSourced

TB-500

A synthetic fragment marketed by association with thymosin beta-4. Full-length thymosin beta-4 findings do not establish an injectable TB-500 protocol.

Evidence context, not a personal protocol

Quantities below reproduce their stated source context—label, human study, laboratory work or educational guide. They do not assess suitability, product equivalence or individual risk.

Dosage and protocol evidence

Each card states what the quantities are based on. A third-party or animal schedule is not a validated human dose.

Community GuideSubcutaneous in guideDaily
Third-party educational TB-500 schedule

500 mcg daily in weeks 1-2, 600 mcg in weeks 3-4, 750 mcg in weeks 5-8 and 1 mg in weeks 9-12

No controlled human TB-500 fragment study validates this schedule. Full-length thymosin beta-4 evidence must not be used as confirmation.

View source

Evidence summary

A synthetic fragment marketed by association with thymosin beta-4. Full-length thymosin beta-4 findings do not establish an injectable TB-500 protocol.

Protocol basis

The central evidence decision is molecule identity: a protocol cannot be imported from a different, full-length protein with different formulation and exposure.

What remains uncertain

Human pharmacokinetics, dose-response, manufacturing standards and controlled outcomes are not established.

Warnings and contraindications

TB-500 fragment identity must not be conflated with full-length thymosin beta-4.
No adequate controlled human injection regimen for TB-500 was identified.
Animal wound-healing experiments do not establish human safety or effectiveness.